Gastric Cancer associated with the use of Omeprazole in Adults
DOI:
https://doi.org/10.56294/piii2024332Keywords:
Omeprazole, Gastric Cancer, Adult, Proton Pump Inhibitors, Epidemilogy, Adverse Effects, Helicobacter PyloriAbstract
Introduction: proton pump inhibitors constitute a group of drugs used to suppress stomach acid secretion and whose consumption has intensified worldwide due to their consideration as the most effective gastric protectors, omeprazole being one of the most widely used.
Objectives: to analyze the existence of gastric cancer risk due to long-term use of omeprazole in adults.
Methods: a search for information was carried out in PubMed and Google Scholar. Search formulas were used by combining the terms: “Omeprazole”, “Cancer Gastric”, “Omeprazole and Adverse effects”, “Omeprazole and Helicobacter Pylori”. From the total number of articles identified, after the screening process, 8 articles were chosen for the present study.
Results: Prolonged treatment with omeprazole can induce histological changes in the gastric mucosa, including hyperplasia, increased gastrin-producing cells, atrophic gastritis and increased colonization of Helicobacter pylori. A rebound acid hypersecretion has been observed after discontinuation of treatment, persisting for at least two months. Endocrine hyperplasia may result from suppression of acid secretion, causing hypergastrinemia and increasing the risk of malignant lesions.
Conclusions: information has been compiled on the effects of prolonged use of omeprazole and its relationship with gastric carcinoma. This use is becoming more frequent, which underlines the need to investigate its long-term effects, since it may alter gastric histoarchitecture and predispose to cancer
References
1. Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21.
2. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. noviembre de 2012;28(6):615-20.
3. Abbas MK, Zaidi ARZ, Robert CA, Thiha S, Malik BH. The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review. Cureus. 4 de septiembre de 2019;11(9):e5563.
4. Crafa P, Franceschi M, Rodriguez-Castro KI, Franzoni L, Russo M, Brandimarte G, et al. PPIs and gastric cancer: any causal relationship? Acta Bio-Medica Atenei Parm. 14 de junio de 2023;94(3):e2023096.
5. Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. noviembre de 2021;70(11):2066-75.
6. Jiang K, Jiang X, Wen Y, Liao L, Liu FB. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol. noviembre de
2019;34(11):1898-905.
7. Paz MFCJ, de Alencar MVOB, de Lima RMP, Sobral ALP, do Nascimento GTM, dos Reis CA, et al. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev. 28 de marzo de 2020;2020:3457890.
8. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. enero de 2018;67(1):28-35.
9. Asian Pacific Journal of Cancer Prevention [Internet]. [citado 9 de enero de 2024]. Disponible en: https://journal.waocp.org/?sid=Entrez:PubMed&id=pmid:15373702&key=2004.5.3.246
10. Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 1 de marzo de 2006;23(5):639-47.
11. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 18 de abril de 1996;334(16):1018-22.
12. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Mashiba H, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther. octubre de 2000;14(10):1345-52.
13. Nishi T, Makuuchi H, Weinstein WM. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett’s esophagus. Tokai J Exp Clin Med. julio de 2005;30(2):117-21.
14. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population- based cohort study in Sweden. BMJ Open. 30 de octubre de 2017;7(10):e017739.
15. Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. octubre de 2019;62:101585.
16. Nandy N, Hanson JA, Strickland RG, McCarthy DM. Solitary Gastric Carcinoid Tumor Associated with Long-Term Use of Omeprazole: A Case Report and Review of the Literature. Dig Dis Sci. marzo de 2016;61(3):708-12.
17. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. febrero de 2009;18(2):526-33.
18. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid Drug Use and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 10 de febrero de 2009;18(2):526-33.
19. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, et al. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol. mayo de 2005;17(5):559- 66.
20. da Mata AMOF, Paz MFCJ, de Menezes AAPM, dos Reis AC, da Silva Souza B, de Carvalho Sousa CD, et al. Evaluation of mutagenesis, necrosis and apoptosis induced by omeprazole in stomach cells of patients with gastritis. Cancer Cell Int. 18 de abril de 2022;22:154.
21. Valido Valdes D, Benítez Falero Y, Junco Sena B, Sánchez Rodríguez Y, Gallardo Romero E. Risk factors for colorectal cancer, a present and a future. AG Salud. 2024;2:49. https://doi.org/10.62486/agsalud202449
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ariel Aníbal Aviza Joaquín, Analía Claudia Sabattini (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
